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Opportunity and cost of
sevelamer in dialysis
patients
To the Editor: Manns et al [1] have recently pointed
out the high cost of replacing by sevelamer, the calcic
phosphate-binder, and the higher prevalence of patients
who would necessitate sevelamer according to K/DOQI
guidelines in America than in Canada, and in hemodialy-
sis patients (66% vs. 54%) than in peritoneal dialysis pa-
tients (60% vs. 38% in U.S. and Canadian patients, respec-
tively). These differences suggest us that it may be due to
higher prevalence of 1 a OH vitamin D use and, more pre-
cisely, of intravenous Calcijex or Zemplar in the U.S.
because of the Medicare reimbursement policy, with only
drugs given during the dialysis session being reimbursed.
Indeed, the Teng Cohort Study [2] pointed out than within
a year, the prevalence of hypercalcemia increased from
6.7% to 8.2%, and that of hyperphosphatemia increased
from 11.9% to 13.9%. This suggests, therefore, that to de-
crease the cost of Ca-phosphate-binder replacement by
sevelamer, the first measure to take would be to prevent
vitamin D insufficiency (thanks to an S 25 OH vitamin
D ≥30 ng/mL as recommended in the K/DOQI), and to
decrease the use of 1 a OH vitamin D mainly by system-
atically not using a dialysate calcium of 1.25 mmol/L, a
concentration known for 31 years to stimulate PTH secre-
tion [3], but rather, using the 1.5 mmol/L concentration
recommended by Argiles [4].
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Economic impact of sevelamer
in patients with ESRD
To the Editor: We read with interest the excellent and
timely article by Manns et al on the economic impact
of the use of sevelamer in ESRD patients [1]. Unfor-
tunately, the authors were unable to include the Cal-
cium Acetate Renagel Evaluation (CARE) study in their
pharmacoeconomics analysis because it was published af-
ter their cut-off date [2]. Likewise, results of the CARE
study were not available during the development of the
current K/DOQI clinical practice guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease
[3].
Given the enormous financial burden of caring for the
ever-increasing dialysis population, it is imperative that
two criteria be met before expanding Medicare benefits to
cover the cost of sevelamer: (1) sevelamer must be shown
to be at least as effective as calcium acetate in achieving
K/DOQI guidelines for serum phosphorus and Ca × P
product; and (2) sevelamer should have documented ben-
eficial effects on the rates of hospitalization and mortality.
Unfortunately, sevelamer has not been shown to meet ei-
ther of these two criteria. In the CARE study, calcium
acetate was clearly more efficacious than sevelamer as a
phosphate binder [2]. Because uncontrolled hyperphos-
phatemia is associated with a number of clinical conse-
quences [4], use of more effective phosphate binders may,
in fact, be associated with lower overall health care cost.
Finally, because the alleged link between calcium load-
ing from use of calcium-based phosphate binders and
cardiovascular calcification has not been substantiated
in well-designed controlled trials, the argument for the
